Neurocrine Biosciences (NBIX) Stock Price, News & Analysis

Company Overview

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and related disorders. The company is headquartered in San Diego, California, and conducts research through internal programs and collaborations with academic institutions and other pharmaceutical companies.

Neurocrine’s principal commercial product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor used to treat tardive dyskinesia and chorea associated with Huntington’s disease. The company also markets ONGENTYS (opicapone), an adjunctive treatment for “off” episodes in adults with Parkinson’s disease receiving levodopa and carbidopa. Its portfolio has also included therapies developed through partnerships, such as elagolix, which was commercialized by AbbVie for certain women’s health conditions.

Founded in 1992, Neurocrine has built its business around treatments for conditions with significant unmet medical needs. In 2024, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) as an adjunctive treatment to glucocorticoid replacement therapy for adults and children with classic congenital adrenal hyperplasia. The company primarily serves the U.S. market while pursuing international commercialization through regional partners and license agreements.

Neurocrine is led by Chief Executive Officer Kyle Gano, who has held leadership positions with the company since joining in 2011.

Key Stats

• Today's Range: $136.31 to $141.07
• 50-Day Range: $138.40 to $185.50
• 52-Week Range: $122.14 to $186.12
• Volume: 1.49 million shs
• Average Volume: 1.21 million shs
• Market Capitalization: $14.06 billion
• P/E Ratio: 20.29
• Dividend Yield: N/A
• Price Target: $202.73
• Consensus Rating: Moderate Buy

Neurocrine Biosciences Stock Analysis - MarketRank™

Neurocrine Biosciences scored higher than 96% of companies evaluated by MarketBeat, and ranked 14th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Neurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 19 buy ratings, 4 hold ratings, and no sell ratings.

Upside Potential

Neurocrine Biosciences has a consensus price target of $201.09, representing about 46.2% upside from its current price of $137.52.

Amount of Analyst Coverage

Neurocrine Biosciences has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 4.4 / 5
• Proj. Earnings Growth: 30.30%

Earnings Growth

Earnings for Neurocrine Biosciences are expected to grow by 30.30% in the coming year, from $7.26 to $9.46 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Neurocrine Biosciences is 20.15, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.73.

Price to Earnings Ratio vs. Sector

The P/E ratio of Neurocrine Biosciences is 20.15, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.94.

Price to Earnings Growth Ratio

Neurocrine Biosciences has a PEG Ratio of 0.65. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Neurocrine Biosciences has a P/B Ratio of 4.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.12% of the float of Neurocrine Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Neurocrine Biosciences has a short interest ratio ("days to cover") of 5.37.

Change versus previous month

Short interest in Neurocrine Biosciences has recently decreased by 1.80%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neurocrine Biosciences does not currently pay a dividend.

Dividend Growth

Neurocrine Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.60

News Sentiment

Neurocrine Biosciences has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Neurocrine Biosciences this week, compared to 8 articles on an average week.

Search Interest

Only 2 people have searched for NBIX on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -69% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,578,064.00 in company stock.

Percentage Held by Insiders

4.60% of the stock of Neurocrine Biosciences is held by insiders.

Percentage Held by Institutions

92.59% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/31/2026
• Today: 9/29/2026
• Next Earnings (Estimated): 10/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:NBIX
• CIK: 914475
• Web: www.neurocrine.com
• Phone: (858) 617-7600
• Fax: 858-617-7602
• Employees: 2,500
• Year Founded: 1992

Price Target and Rating

• Average Price Target for Neurocrine Biosciences: $202.73
• High Price Target: $253.00
• Low Price Target: $160.00
• Potential Upside/Downside: +46.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 24 Analysts

Profitability

• EPS (Trailing Twelve Months): $6.82
• Trailing P/E Ratio: 20.29
• Forward P/E Ratio: 19.06
• P/E Growth: 0.65
• Net Income: $478.60 million
• Net Margins: 20.91%
• Pretax Margin: 27.87%
• Return on Equity: 22.43%
• Return on Assets: 15.64%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.87
• Quick Ratio: 1.75

Sales & Book Value

• Annual Sales: $2.86 billion
• Price / Sales: 4.92
• Cash Flow: $5.01 per share
• Price / Cash Flow: 27.61
• Book Value: $32.63 per share
• Price / Book: 4.24

Miscellaneous

• Outstanding Shares: 101,650,000
• Free Float: 96,973,000
• Market Cap: $14.06 billion
• Optionable: Optionable
• Beta: 0.38